Skip to main content

Table 1 Characteristic of patient entering into Phase I with matched therapy

From: Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials

No.

Cancer type

Molecular alteration

Matched therapy

Response

Progression free survival (month)

1

Bile duct

FGFR2

FGFR inhibitor

PD

0.95

2

Cervical

PIK3CA

E542K

PI3K inhibitor

NE

2.53

3

Liver

TSC1

mTOR inhibitor

NE

0.82

4

Breast

BRCA1

PARP inhibitor

PR

8.09

5

Peritoneal

BRCA1

PARP inhibitor

SD

7.17

6

Cervical

PIK3CA

E542K

AKT inhibitor

PD

0.72

7

Breast

PIK3CA

H1047R

PI3K inhibitor

PR

6.18

8

Breast

PIK3CA

E545K

PI3K inhibitor

SD

2.80

9

Breast

PIK3CA

E545V

PI3K inhibitor

SD

5.72

10

Breast

AKT1

E17K

AKT inhibitor

PR

14.1

11

Breast

BRCA1

PARP inhibitor

SD

5.53

  1. PD progression disease, SD stable disease, PR partial response, NE not evaluable